-
Mashup Score: 1
The SATURN trial examined the addition of dual ARPIs and metastasis-directed SBRT to intermittent ADT to determine if the combination can improve recurrence rates over ADT alone.
Source: guoncologynow.comCategories: General Medicine News, Onc News and JournalsTweet
🔬 New data from the phase 2 #SATURN trial examined the addition of dual #ARPIs and metastasis-directed #SBRT to intermittent #ADT to determine if the combination can improve recurrence rates over #ADT alone for patients with #mHSPC. 📰 Read Now: https://t.co/htRSnl5FXB https://t.co/BUlDS8oUSW